Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?

被引：18

作者：

Templeton, I. E. ^{[1
]}

Chen, Y. ^{[1
]}

Mao, J. ^{[1
]}

Lin, J. ^{[2
]}

Yu, H. ^{[3
]}

Peters, S. ^{[4
]}

Shebley, M. ^{[5
]}

Varma, M. V. ^{[2
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

[2] Pfizer Inc, Groton, CT 06340 USA

[3] Boehringer Ingelheim Pharmaceut, Ridgefield, CT USA

[4] AstraZeneca, Molndal, Sweden

[5] AbbVie Inc, N Chicago, IL USA

来源：

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY | 2016年 / 5卷 / 10期

关键词：

D O I：

10.1002/psp4.12110

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

This subteam under the Drug Metabolism Leadership Group (Innovation and Quality Consortium) investigated the quantitative role of circulating inhibitory metabolites in drug-drug interactions using physiologically based pharmacokinetic (PBPK) modeling. Three drugs with major circulating inhibitory metabolites (amiodarone, gemfibrozil, and sertraline) were systematically evaluated in addition to the literature review of recent examples. The application of PBPK modeling in drug interactions by inhibitory parent-metabolite pairs is described and guidance on strategic application is provided.

引用

页码：505 / 515

页数：11

共 50 条

[21] Physiologically based pharmacokinetic modeling of ponatinib to describe drug-drug interactions in patients with cancer
Morita, Tomoko O.
Hanada, Kazuhiko
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 90 (04) : 315 - 323
[22] APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING IN PREDICTING DRUG-DRUG INTERACTIONS FOR TELMISARTAN IN HUMANS
Kim, Jeong Ho
Heo, Hyunjin
Min, Jee Sun
Kim, Doyun
Bae, Soo Hyeon
Bae, Soo Kyung
DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S109 - S110
[23] Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
Cicali, Brian
Lingineni, Karthik
Cristofoletti, Rodrigo
Wendl, Thomas
Hoechel, Joachim
Wiesinger, Herbert
Chaturvedula, Ayyappa
Vozmediano, Valvanera
Schmidt, Stephan
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (01): : 48 - 58
[24] Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
Zhou, D.
Bui, K.
Sostek, M.
Al-Huniti, N.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2016, 5 (05): : 250 - 257
[25] Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib
Liu, Hongrui
Yu, Yiqun
Guo, Nan
Wang, Xiaojuan
Han, Bing
Xiang, Xiaoqiang
FRONTIERS IN PHARMACOLOGY, 2021, 12
[26] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF ATORVASTATIN AND RELATED SPECIES AND PREDICTION OF DRUG-DRUG INTERACTIONS IN HUMANS.
Morse, B. L.
Alberts, J. J.
Kolur, A.
Posada, M. M.
Tham, L.
Loghin, C.
Hall, S. D.
Dickinson, G. L.
Hillgren, K. M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S63 - S64
[27] Predicting Drug-Drug Interactions Involving Multiple Mechanisms Using Physiologically Based Pharmacokinetic Modeling: A Case Study With Ruxolitinib
Shi, J. G.
Fraczkiewicz, G.
Williams, W. V.
Yeleswaram, S.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (02) : 177 - 185
[28] Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction
Chen, Yuan
Ma, Fang
Lu, Tong
Budha, Nageshwar
Jin, Jin Yan
Kenny, Jane R.
Wong, Harvey
Hop, Cornelis E. C. A.
Mao, Jialin
CLINICAL PHARMACOKINETICS, 2016, 55 (06) : 735 - 749
[29] Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes
Catia Marzolini
Rajith Rajoli
Manuel Battegay
Luigia Elzi
David Back
Marco Siccardi
Clinical Pharmacokinetics, 2017, 56 : 409 - 420
[30] Role of inhibitory metabolites in drug-drug interactions
Isoherranen, Nina
DRUG METABOLISM REVIEWS, 2006, 38 : 6 - 7

← 1 2 3 4 5 →